Abstract
Background
Depression is more common in diabetic patients, with a 1.5-fold increased risk of death.Melissa officinalis (M. officinalis) have anti-diabetic and anti-depression activities. The study aimed to determine the efficacy of M. officinalis extract on depression, anxiety, and sleep quality in patients with type 2 diabetes with depressive symptoms.
Methods
In this double-blind clinical trial, 60 volunteer patients (age range 20–65 years) with type 2 diabetes mellitus with symptoms of depression were randomized into the intervention (received 700 mg/day hydroalcoholic extract; n = 30) or control group (received 700 mg/day toasted flour; n = 30). Dietary intake, physical activity, anthropometric indices, FBS (Fasting blood sugar), hs-CRP(High-sensitivity C-reactiveprotein), depression, anxiety, and sleep quality were determined at the beginning and end of the study. Depression and anxiety were assessed by Beck Depression Inventory-II (BDI-II) and Beck Anxiety Inventory (BAI), respectively; sleep quality was evaluated using the Pittsburgh Sleep Quality Index (PSQI).
Results
Sixty participants received M. officinalis extract or placebo, of which 44 patients completed the 12-week double-blind clinical trial. After 12-week the mean change of depression and anxiety scores were statistically significant between the two groups (p < 0.001 and p = 0.04, respectively), but no significant differences were observed in FBS, hs-CRP, anthropometric indices, sleep quality, and blood pressure.In the intervention group, there was a significant decrease in depression and anxiety severity(p < 0.001 and p = 0.01, respectively) at the end of the study compared to the baseline.
Trial registration
All protocols in this study were followed in accordance with the Helsinki Declaration (1989 revision). Ethical approval for this study was obtained from the Iran University of Medical Sciences Ethics committee (IR.IUMS.FMD.REC 1396.9413468004; research.iums.ac.ir). The study was registered at the Iranian Registry of Clinical Trials (IRCT201709239472N16); Registration date: 09/10/2017.
Supplementary Information
The online version contains supplementary material available at 10.1186/s12906-023-03978-x.
Keywords: Diabetes, Melissa officinalis, Depression, Anxiety, Sleep quality, Lemon balm
Background
The attendance of depression and anxiety in diabetic patients deteriorates the prediction of diabetes. Depression is higher among diabetic patients than in the general population [1]. A recent study in Iranian diabetic patients revealed that the prevalence of depression and anxiety in diabetes mellitus patients was estimated to be 24/4% and 64/5%, respectively [2]. The appearance of depression in diabetic patients is associated with poorer medication adherence [3], impaired glycemic control [4] and increased diabetes complications [3]. Diabetes-related quality of life is low in patients with depressive symptoms and sleep disorders [5].
Depression is linked with a 1.5-fold increased mortality risk in people with diabetes [6]. Furthermore, high levels of serum inflammatory markers such as hs-CRP are associated with mood disorders and chronic diseases such as cardiovascular diseases [7]. Hayashino et al. have reported that raised levels of hs-CRP are associated with a high prevalence of depression in patients with type 2 diabetes(T2D) [8]. Therefore, appropriate treatment of depression, anxiety, and inflammation in diabetic patients is required. On the other hand, proper approaches for both depression and diabetes problems are assumed to be more efficient than treating depression alone [9]. Antidepressant drug usage in T2D patients may have adverse side effects [10, 11]. Thus, there is a necessity for more effective treatment procedures for depression in T2D patients, which improves both psychiatric signs and complications of diabetes.
Currently, complementary and alternative medicine is widely used in the management of chronic diseases[12]. A study reported that 40% of adults with depression progressively use complementary and alternative medicine (CAM) therapies [13]. Accordingly, it is necessary to use a combination of therapeutic methods to achieve the highest effect in diabetic patients [14]. Many researches have being conducted to discover effective drugs with fewer side effects [12].
Melissaofficinalis also known as lemon balm is a plant belonging to the Lamiaceae family with potent anti‐inflammatory M. officinalis may have both anti-depressive and anti-diabetic effects. [15], antioxidant [16], anti-depression and anti-anxiety effects [17].
The main identified components of lemon balm are stated to be geranyl acetate, citral, citronellal, geraniol, nerol, linalool, citronellal,citronellol and rosmarinic acid [18].
Animal studies have demonstrated the anti-diabetic and anti-hyperlipidemic effects of M. officinalis [19, 20]. Also, recent clinical trials have shown that M. Officinalis has anti-diabetic and anti-depression activities and cardiovascular protective effects [15, 21–24]. Two clinical trials have reported that M. officinalis have an essential effect on reducing of hs-CRP in patients with type 2 diabetes and patients with chronic stable angina [15, 25]. However, no clinical trials have examined M. officinalis on depression, anxiety, sleep quality, and hs-CRP in patients with type 2 diabetes with depression symptoms. In the present study, we aimed to explore the effects of hydroalcoholic extract of M. officinalis aerial parts on depression and anxiety severity in type 2 diabetic patients with depressive symptoms.
Materials and methods
Preparation of plant extract
The M. officinalis aerial parts were prepared. After washing, drying, and powdering, the extract preparation was carried out using hydro-alcoholic (70%) solvent [24] by the Institute of Medicinal Plant Karaj Iran.
In brief, to the determination of total flavonoids and the main component of M. officinalis, the aliquot of the appropriately diluted extract (1 mL) or standard solutions of rutin in methanol (50, 100, 150, 200, and 250 mg/ml) were mixed with 4 ml of distilled water in a 10‐ ml volumetric flask. In the beginning, 0.3 ml of 5% (w/v) sodium nitrite was added to the flask. After 5 min, 0.3 ml of 10% (w/v) aluminum chloride (AlCl3) was added, and after 6 min, 2 ml of 1 M NaOH was also added to the mixture. The process was developed by the addition of 3.4 ml of distilled water. The absorbance of the pink color mixture was reported at 510 nm against prepared water blank. The flavonoid contents were revealed as milligram rutin equivalent per gram of the extract.
Besides, the amount of rosmarinic acid in the extract capsule was quantified by HPLC according to previously detailed techniques [26].
Ethics approval and consent to participate
All protocols in this study were followed conducted in accordance with the Helsinki Declaration (1989 revision) and Ethical approval for this study was obtained from the Iran University of Medical Sciences Ethics committee (IR.IUMS.FMD.REC 1396.9413468004; research.iums.ac.ir). The study was registered at the Iranian Registry of Clinical Trials (IRCT201709239472N16;). All participants were informed of the study's purposes and signed written informed consent.
Participants
Participants were 60 patients with type 2 diabetes combined with depression. The study was carried out at the Endocrine Research Center, Institute of Endocrinology and Metabolism, Iran University of Medical Sciences in Tehran, between May 2017 and May 2019. The Inclusion criteria were: type 2 diabetes patients with at least one year of DMT2 history, aged 20 to 65 years for both genders; the presence of depressive symptoms (depression score of more than ten based on Beck Depression Inventory) [27], the body mass index less than 35 kg/m2; triglycerides less than 400 mg/dl; HbA1c < % 8; no smoking or use of alcohol; no use of any dietary supplement for at least three months prior to baseline; using hypoglycemic agents but not insulin; not taking an antidepressant, sedative, and anxiolytic drugs. The participants were excluded if they had the following criteria: having a history of psychiatric and neurological disorders (such as severe depression and anxiety and suicidal thoughts), having any co-disorders including renal, cardiovascular, liver, thyroid disorders,and infectious diseases as well as allergic and glaucoma; using nonsteroidal anti-inflammatory drugs (NSAIDs) or estrogen and progesterone; pregnancy or lactation; taking < 80% of supplements delivered to the patient. Subjects using hypolipidemic and antihypertensive medications were incorporated. They were requested not to alter the kind or the dose of all drugs and not to change their diet and physical activity level during the intervention period.
Study design
We conducted a single-center, randomized, and double-blind clinical trial. Participants, researchers, and statisticians were blinded. All subjects were initially randomly assigned by simple randomization procedures (computerized random numbers) to the intervention group (M. officinalis) or control group (toasted flour) in a 1:1 ratio. To avoid ethical problems, all participants were invited to an educational session to receive general points about anxiety and depression by the psychologist before intervention.
Patients in M. officinalis group received two capsules (daily) containing 350 mg hydroalcoholic extract powder of M. officinalis, and patients in the placebo group took two capsules (daily) containing 350 mg of toasted flour. All patients were advised to take capsules twice a day after lunch and dinner for 12 weeks. The M. officinalis and placebo capsules were completely similar in appearance. During the intervention, all participants in the study were followed up by telephone interviews weekly to ensure the ordered and appropriate utilization of the investigation protocol drugs and respond to the patients’ questions if required. Physical activity was estimated using the International Physical Activity Questionnaire (IPAQ), in the beginning, six weeks, and 12 weeks. Daily energy intake, micronutrients, and macronutrients were measured using a 24-h diet recall questionnaire in 3 days (two regular days and one holiday) at baseline, six weeks, and 12 weeks. A skilled nutritionist completed each questionnaire. The dietary data were analyzed by the N4 software (Nutritionist 4, First Data Bank, San Bruno, CA, USA). At the baseline and after 12 weeks of study, the Beck Depression Inventory-II (BDI–II), Beck Anxiety Inventory (BAI), and Pittsburgh Sleep Quality Index (PSQI) questionnaires were completed to define the presence and severity of depression, anxiety, and sleep quality, respectively. The (BDI–II) is a 21-item questionnaire with a scale from 0 to 3 for each item. Based on this, test scores between 0 and 9, 10–19, 20–29,and 30–63 stand for normal, mild, moderate, and severe depression, respectively[28]. Beck Anxiety Inventory is a 21-item questionnaire with a scale from 0 to 3 for each item that measures anxiety signs such as nervousness and fear of losing control. It explains the emotional, physiological, and cognitive signs of anxiety, indicating anxiety's intensity in adults and adolescents. The scores of 0–21, 22–35, and 35–63 demonstrate mild, moderate, and severe anxiety, respectively[29].
Furthermore, the validated Persian language version [30] of PSQI was used to estimate sleep quality. This questionnaire includes seven major issues: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medications, and daytime dysfunction. Scoring is based on a scale from 0 to 3 for each item. The sum of scores higher than five shows sleep disorders [31].
Venous blood samples were collected after 12 to 14 h of overnight fasting before and after 12 weeks of intervention. The serum samples for measuring FBS and hs-CRP were frozen at -80 ˚C until measurement. Systolic and diastolic blood pressure were recorded after rest (at least 5 min), in the sitting position, using an OMRON M6 Comfort Automatic Blood Pressure Monitor (Tokyo, Japan) at baseline and after 12 weeks of study. Participants' weight and height were measured by using a standard calibrated scale (Seca, Hamburg, Germany) and Waist circumference (WC) were assessed by a practiced researcher. Body mass index (BMI) was calculated according to the following equation BMI = weight (kg)/length2 (m2).
Sample size
A sample size of at least 25 patients per group was calculated, giving a power of 80% to detect the target difference in depression (as a critical variable obtained from a previous study) [16] at the 5% significance level.Predicting 15% dropouts in each group, the final sample size was estimated to be 30 partners in each study group.
Patients were assigned into two groups using permuted block randomization with two size blocks (case and control) and a random number table. To hide the treatment, the statistical advisor who was not involved in the study encoded the identical boxes of the capsules and generated the random sequence. Randomization and allocation were hidden from both the researchers and the patients until the final analyses were completed. The randomized allocation sequence, enrollment of patients, and allocation to interventions were operated by trained staff.
Laboratory analysis
FBS was calculated with a Cobas MIRA analyzer (Roche Diagnostic, Basel, Switzerland) by an enzymatic process (Pars Azmon Co., Tehran, Iran). The sensitivity of the assays for FBS was 5 mg/dL. hs-CRP was calculated by using the turbidimetric method the Pars Azmoon kit (Pars Azmoon Inc., Tehran, Iran) on Hitachi 917. The sensitivity of the assays for hs-CRP was 0.1 mg/L.
Statistical analysis
The Kolmogorov–Smirnov test was done to investigate the normality of data. Between‐group comparisons of quantitative variables and their mean changes were made using independent samples t-test or Mann–Whitney U test for normally and non-normally distributed data, respectively. A Comparison of qualitative variables and their mean changes between the groups was done using the Chi‐square test and Fisher exact test. Within‐group comparisons were done using paired samples t-test or Wilcoxon signed‐ranks test for normally and non-normally distributed data, respectively. Results were expressed as mean ± standard deviation. All statistical analyses were assessed by Statistical Package for Social Science version 24 (SPSS Inc., Chicago, IL, USA).P-values equal or less than 0.05 were considered statistically significant.
Results
Participants’ baseline characteristics the main results
Forty-four participants completed the study (intervention group:23 and control group: 21). Figure 1 Shows the flow of participants from registration to the end of the study. Sixteen subjects lost the follow-up and were excluded from the study (7 in the HEMO group and 9 in the placebo group) for the following reasons: unwillingness to cooperate (n = 9), pregnancy (n = 1), cold (n = 2), need for insulin therapy (n = 2), and change their diet (n = 2). Finally, 44 subjects successfully finished the follow-up, and their data were applied for the statistical analysis.
Fig. 1.
Flow of patients from enrollment to the end of the study
The patients' basic characteristics, including weight, body mass index, age, disease duration, physical activity, and medications, between the two groups in the M. officinalis and placebo groups did not differ significantly (Table 1). There were no significant changes in physical activity (based on METs) and nutrient intake during the intervention (for details, see Table 2 and 3, respectively). There was no significant difference between the two groups with regard to drug type.
Table 1.
General characteristics of T2DM patients at baseline
| Variable | HEMO (n = 23) | Placebo (n = 21) | p Value | |
|---|---|---|---|---|
| Age (yr) | 52.65 ± 6.14 | 54.19 ± 5.99 | 0.53‡ | |
| Male/Female N (%) | 9(39.1)/14(60.9) | 10(47.6)/11(52.4) | 0.57** | |
| Duration of diabetes (yr) | 6.26 ± 3.1 | 6.76 ± 4.47 | 0.66‡ | |
| Hypolipidemic agents N (%) | Metformin | 6 (26.1) | 10 (47.6) | 0.37** |
| Metformin + Glibenclamide | 14 (60.9) | 10 (47.6) | ||
| Metformin + Repaglinide | 2 (8.7) | 0 (00) | ||
| Metformin + Glibenclamide + Repaglinide | 1 (4.3) | 1 (4.8) | ||
| Hypolipidemic agents N (%) | Atorvastatin | 17 (73.9) | 15 (71.4) | 0.85** |
| Hypotensive agents N (%) | Losartan | 10 (43.5) | 10 (47.6) | 0.78** |
Values are presented as mean ± standard deviation or n (%). P-valuses based on: ‡Independent t test; t; ** Fisher’s exact test
HEMO hydroalcoholic extract of M. officinalis, WC Waist circumference
Table 2.
Physical activity comparison at baseline, middle, and end of study between the two groups
| Variable | Baseline | Middle | End | |||
|---|---|---|---|---|---|---|
| HEMO | Control | HEMO | Control | HEMO | Control | |
| Low-PA N (%) | 11 (47.8) | 6 (28.6) | 12 (52.2) | 6 (28.6) | 10 (43.5) | 16 (51.6) |
| Moderate-PA N (%) | 8 (34.8) | 12 (57.1) | 5 (21.7) | 12 (57.1) | 8 (34.8) | 11 (35.5) |
| High-PA N (%) | 4 (17.4) | 3 (14.3) | 6 (26.1) | 3 (14.3) | 5(21.7) | 4 (12.9) |
| P value* | 0.33 | 0.06 | 0.60 | |||
Values are presented as n (%). There were no significant differences of physical activity between the M. officinalis and placebo groups (P > 0.05), based on: Fisher’s exact test*. PA Physical activity, HEMO hydroalcoholic extract of M. officinalis
Table 3.
Energy and nutrients intake at baseline, in the middle and at the end of the study
| Nutrients | Group | Baseline Mean ± SD |
Middle Mean ± SD |
End Mean ± SD |
##P value | ||
|---|---|---|---|---|---|---|---|
| Baseline | Middle | End | |||||
|
Energy (kcal) |
HEMO | 1633.50 ± 228.24 | 1613.63 ± 149.35 | 1612.45 ± 150.90 | 0.72‡ | 0.86‡ | 0.95‡ |
| Control | 1612.64 ± 153.05 | 1621.09 ± 133.50 | 1614.66 ± 134.36 | ||||
| Protein (g) | HEMO | 63.32 ± 11.54 | 64.38 ± 9.82 | 61.77 ± 8.43 | 0.7‡ | 0.09‡ | 0.69‡ |
| Control | 62.15 ± 8.68 | 60.330 ± 5.54 | 60.78 ± 8.15 | ||||
|
Carbohydrate (g) |
HEMO | 229.20 ± 33.76 | 2330.92 ± 27.68 | 231.90 ± 25.72 | 0.58‡ | 0.52‡ | 0.37‡ |
| Control | 234.65 ± 32.12 | 236.74 ± 32.13 | 239.46 ± 31.69 | ||||
| Total fat (g) | HEMO | 49.5 ± 9.62 | 50.39 ± 8.25 | 50.94 ± 9.15 | 0.55‡ | 0.97‡ | 0.78‡ |
| Control | 50.95 ± 11.19 | 50.47 ± 8.37 | 51.68 ± 8.23 | ||||
| Fibre (g) | HEMO | 15.45 ± 3.19 | 16.88 ± 3.11 | 15.52 ± 3.14 | 0.49‡ | 0.64‡ | 0.24‡ |
| Control | 16.9 ± 2.87 | 16.41 ± 3.47 | 16.70 ± 3.37 | ||||
| SFA (g) | HEMO | 15.74 ± 3.73 | 15.92 ± 3.73 | 16.2 ± 3.52 | 0.63‡‡ | 0.69‡‡ | 0.35‡ |
| Control | 14.81 ± 2.72 | 15.07 ± 2.44 | 15.11 ± 2.86 | ||||
| MUFA (g) | HEMO | 14.35 ± 3.50 | 14.48 ± 2.92 | 14.67 ± 3.14 | 0.94‡ | 0.91‡ | 0.74‡ |
| Control | 14.28 ± 2.98 | 14.39 ± 2.64 | 14.36 ± 3.01 | ||||
| PUFA (g) | HEMO | 13.85 ± 3.74 | 14.05 ± 3.91 | 14.07 ± 3.05 | 0.08‡‡ | 0.47‡ | 0.34‡ |
| Control | 15.27 ± 3.62 | 14.88 ± 3.74 | 15.19 ± 2.99 | ||||
|
Vitamin C (mg) |
HEMO | 109.57 ± 65.87 | 119.84 ± 63.19 | 118.10 ± 56.47 | 0.61‡ | 0.68‡ | 0.77‡ |
| Control | 118.16 ± 44.38 | 113.54 ± 34.83 | 113.65 ± 44.96 | ||||
|
Vitamin E (mg) |
HEMO | 6.26 ± 2.99 | 6.60 ± 2.93 | 6.86 ± 3.54 | 0.35‡‡ | 0.97‡‡ | 0.64‡‡ |
| Control | 7.47 ± 4.08 | 7.34 ± 4.32 | 7. 37 ± 4.02 | ||||
|
Selenium (mg) |
HEMO | 0.076 ± 0.03 | 0.074 ± 0.03 | 0.074 ± 0.02 | 0.92‡ | 0.99‡ | 0.77‡ |
| Control | 0.077 ± 0.02 | 0.074 ± 0.01 | 0.072 ± 0.01 | ||||
Values expressed as mean ± SD.##P. Value for variable comparing between the two groups baseline, in the middle and at the end of the intervention. Calculated by ‡Independent T-Test and ‡‡ Mann–Whitney U test
HEMO hydroalcoholic extract of M. officinalis, SFA saturated fatty acid, MUFA monounsaturated fatty acid, PUFA polyunsaturated fatty acid
Effect of M. officinalis extract on study outcomes
The mean and standard deviation of clinical and biochemical features within and between groups are presented in Table 4. There were no statistically significant differences in all of the patients' biochemical parameters, depression, anxiety, sleep quality, and blood pressure (systolic and diastolic) between the two groups at the baseline (P-value > 0.05). After the study in intervention group compared with the placebo group, Significant reductions were found in anxiety and depressive symptoms. The mean changes showed significant between-group differences in scores of the BDI (P < 0.001) and BAI (P = 0.04) questionnaires, but between-group differences of the mean values in fasting blood sugar, hs-CRP, sleep quality, blood pressure (systolic and diastolic) and, anthropometric values (weight, BMI, and WC/Hip) were non-significant (Table 4). Furthermore, the Beck scores of depression and anxiety showed a significant reduction in the M. officinalis group compared with the beginning of the study. (P < 0.001 and P = 0.01, respectively). We failed to find any significant effect of supplementation on hs-CRP, sleep quality, and blood pressure (Table 4). No side effects were reported by the patients.
Table 4.
Comparisons of clinical and biochemical features before and after 8 weeks intervention
| Variable | HEMO (Mean ± SD) | Placebo (Mean ± SD) | p Value∏ | |
|---|---|---|---|---|
| Weight (kg) | Before | 77.41 ± 14.98 | 77.42 ± 13.09 |
0.63 0.31 ‡‡ |
| After | 75.78 ± 15.29 | 77.80 ± 12.60 | ||
| mean change | -1.63 ± 6.75 | 0.38 ± 1.96 | ||
| p Value## | 0.19▲ | 0.18▲ | ||
| BMI (kg/m2) | Before | 28.61 ± 4.34 | 28.34 ± 3.96 |
0.52 0.11 |
| After | 28.03 ± 4.30 | 28.53 ± 3.80 | ||
| mean change | -0.58 ± 2.57 | 0.19 ± 0 .73 | ||
| p Value## | 0.97▲ | 0.21▲ | ||
| WC/Hip | Before | 0.93 ± 0.04 | 0.93 ± 0.05 |
0.63 0.62 ‡‡ |
| After | 0.93 ± 0.04 | 0.93 ± 0.05 | ||
| mean change | 0.001 ± 0.02 | 0.004 ± 0.03 | ||
| p Value## | 0.26▲ | 0.93▲ | ||
| FBS (mg/d) | Before | 146.26 ± 35.77 | 140.61 ± 37.69 |
0.75 0.75 ‡‡ |
| After | 149.82 ± 33.56 | 150.76 ± 35.34 | ||
| mean change | 3.57 ± 16.22 | 10.62 ± 18.79 | ||
| p Value## | 0.30▲ | 0.02▲ | ||
| Depression | Before | 18.00 ± 10.30 | 14.28 ± 5.11 |
0.52 0.001 ‡‡ |
| After | 14.08 ± 7.63 | 14.23 ± 5.43 | ||
| mean change | -3.91 ± 4.48 | -0.04 ± 2.67 | ||
| p Value## | 0.001▲ | 0.71▲ | ||
| Anxiety | Before | 11.82 ± 8.10 | 8.09 ± 5.32 |
0.79 0.04 ‡‡ |
| After | 9.78 ± 7.60 | 8.33 ± 5.69 | ||
| mean change | -2.04 ± 3.49 | 0.23 ± 3.75 | ||
| p Value## | 0.01▲ | 0.51▲ | ||
| Sleep Quality | Before | 4.69 ± 2.56 | 4.61 ± 3.89 |
0.97 0.15 ‡‡ |
| After | 4.00 ± 2.21 | 4.42 ± 3.32 | ||
| mean change | -0.69 ± 1.74 | -0.19 ± 1.20 | ||
| p Value## | 0.08▲ | 0.58▲ | ||
| Hs-CRP (mg/L) | Before | 1.95 ± 1.84 | 2.13 ± 2.82 |
0.63 0.11 ‡‡ |
| After | 1.60 ± 1.86 | 2.20 ± 2.51 | ||
| mean change | -0.34 ± 1.03 | 0.65 ± 0.75 | ||
| p Value## | 0.13▲ | 0.62▲ | ||
|
Systolic blood pressure (mm Hg) |
Before | 13.84 ± 2.05 | 12.92 ± 1.42 |
0.69 0.06 ‡‡ |
| After | 13.52 ± 1.95 | 13.50 ± 1.64 | ||
| mean change | -0.32 ± 1.49 | 0.57 ± 1.49 | ||
| p Value## | 0.28▲ | 0.11▲ | ||
|
Diastolic blood pressure (mm Hg) |
Before | 8.58 ± 1.19 | 8.11 ± 1.27 |
0.62 0.26 ‡‡ |
| After | 8.48 ± 1.22 | 8.33 ± 1.16 | ||
| mean change | -0.1 ± 0.83 | 0.21 ± 0.71 | ||
| p Value## | 0.93▲ | 0.20▲ | ||
Values are presented as mean ± standard deviation. p Value∏ (p < 0.05) for variable comparing between the two groups at the end of the intervention.p Value## for variable comparing within the two groups at the end of the intervention. Calculated by ▲Wilcoxon signed-ranks test. p Value‡‡ for mean changes comparing between the two groups at the end of the intervention
BMI body mass index, WC waist circumference, FBS fasting blood sugar, HEMO hydroalcoholic extract of M. officinalis; hs-CRP high-sensitivity C-reactive protein, DBP diastolic blood pressure, SBP systolic blood pressure
Extract analysis
The total flavonoid contents of M. officinalis aerial parts as milligrams rutin equivalent per gram was 148.06 mg rutin/gr. The total phenolic content of the extract as a milligram of rosmarinic acid per capsule was 8.10 ± 0. 04 (mean ± SD).
Discussion
The incidence of depression in diabetic patients significantly impacts glycemic control, adverse events, and quality of life in these patients. The combination of diabetes and depression increases the risk of death in these patients. We performed this study as the first clinical trial to reveal the clinical efficacy of 700 mg/bid. M. officinalis supplementation in type 2 diabetes patients with depression symptoms. Patients were controlled for side effects, and no serious adverse outcomes were reported during the study. The findings of this study showed that supplementation with 700 mg daily of lemon balm extract capsule significantly reduced scores of the BDI and BAI questionnaires in diabetic patients in the intervention group.
In line with our findings, Chehroudi et al. [16] reported that 20 days of treatment with M. officinalis in the form of a tea-bag (2.5 gr per tea-bag) twice a day reduced depression and anxiety and improved sleep quality in thirty-six patients with second and third-degree burns with 35 to 55% total body surface area (TBSA) who suffered from anxiety, depression, and insomnia. Anxiety, depression, and insomnia levels were evaluated by the Kettles, Beck, and Petersburg questionnaires, respectively.
Besides, Taiwo et al. [32] reported that oral ingestion of M. officinalis ethanol extract (30, 100, or 300 mg/kg) has anxiolytic and antidepressant-like properties in rats.
One of the main causes of depression that is nowadays highlighted is an increase in cortisol levels and a change in the cycle of cytokines such as gamma-aminobutyric acid and glutamate [33]. It has been shown that lemon balm reduces corticosterone levels and increases gamma amino-butyric acid levels which are the most valuable biomarkers correlated with physiological stress, confirming a phytotherapy effect [34]. Furthermore, in the study of Alijani et al. [35], consumption of 500 mg of lemon balm extract for 14 days, significantly reduced anxiety in patients with chronic heart palpitation. Also, Cases et al. [36] showed that 600 mg of Cyracos, a standardized M. officinalis extract for 15 days could improve anxiety manifestations, anxiety-associated symptoms, and insomnia in 20 stressed volunteers who were impressed with mild-to-moderate anxiety disorders and sleep disturbances.
Our results also exhibited that the study intervention did not significantly affect sleep disorders. This finding can be associated with the small sample size of the study. One of the main causes of anxiety is neurobiological disorders such as serotonin, gamma-aminobutyric acid and noradrenaline system disturbance [37]. Rosmarinic acid in lemon balm increases GABAergic levels by inhibiting gamma-aminobutyric acid transaminase (GABA-T)[38]. Dysfunction in GABA-A receptors is associated with symptoms of anxiety and sleep disorder [39]. The ethanolic extract of lemon balm has moderate activity in binding to the GABA-A receptor, that the anxiolytic and hypnotic effect of lemon balm may be due to binding to the GABA-A receptor [40].
Supplementation had no significant effect on FBS in the lemon balm group. There are some controversial reports on the effects of M. officinalis supplementation on FBS. There were no significant changes in FBS in Jandaghi[22], Yui[41], and Nayebi[23] studies in patients with borderline hyperlipidemia and healthy adults and patients with type 2 diabetes mellitus, respectively. However, Asadi et al. [15] reported that the hydroalcoholic extract of lemon balm could suppress the increases in FBS levels in patients with type 2 diabetes mellitus. However, in experimental studies [19–21, 42], M. officinalis had hypoglycemic effects on diabetic animals. A probable mechanism for glycemic indexes of lemon balm may be due to its effects on increased expression of hepatic glucokinase, GLUT4(Glucose transporter type 4), as well as decreased expression of glucose 6-phosphatase and phosphoenolpyruvate carboxykinase[19].
In the present study, the reduction of hs-CRP in the M. officinalis group was not significant. However, three randomized clinical trials reported the beneficial effects of M. officinalis on hs-CRP in patients with type 2 diabetes, patients with chronic stable angina, and young trained swimmers [15, 25, 43]. This difference may be due to several factors such as differences in sample size, M. officinalis dose, duration of the study, and severity of diabetes and depression.
Some components in M. officinalis may have anti-inflammatory activity [44]. We found rosmarinic acid as one of the main components of the extract in each capsule. Studies have explicated that rosmarinic acid inhibits NF-κB nuclear transcription factor, thereby reducing inflammation [45].
There is also controversy about M. officinalis effects on blood pressure and anthropometric indicators. The results of our study showed that supplementation with M. officinalis had no significant effect on blood pressure and anthropometric indicators. In favor of our study, Javid et al. [25] reported that 8-week therapy with 3 g/d oral M. officinalis had no significant effects on blood pressure and BMI. As well as in a study conducted by Nayebi et al. [23], oral M. officinalis at a dose of 1000 mg/day for 12 weeks had no significant effect on blood pressure and BMI in 32 patients with type 2 diabetes. In the study of Jandaghi et al. [22], the consumption of 3 g of lemon balm powder by hyperlipidemic subjects for two months did not affect body weight and BMI.
Nevertheless, a recent study revealed the antihypertensive effects of 700 mg of M. officinalis hydroalcoholic extract on type 2 diabetes patients[15]. In experimental animals, some studies [20, 42] revealed that M. officinalis could not decrease BMI. However, the results of the study of Park et al. [46] showed that lemon balm extract (standardized with rosmarinic acid and caffeic acid) at doses of 4 gr (200 mg/kg/d) and 8 gr (400 mg/kg/d) could prevent gaining weight of rats and reduces adipose tissue and size of adipocytes.
Strengths and limitations
Evaluation of dietary intakes and physical activity in the baseline, middle, and end of the study can be counted as the powers of our research; Nevertheless, inadequate M. officinalis extract dose, and small sample size were the main limitations of this study. Furthermore, BDI–II may point a false positive results in assessing depression in diabetic patients [47] and tools such as HADS may be more appropriate tools [48].
Conclusions
The results of this study showed that the use of 700 mg of the hydroalcoholic extract of the aerial parts of M. officinalis daily for 12 weeks by diabetes patients with depression symptoms reduced the depression and anxiety status. However, larger clinical trials are needed to detect the effects of M. officinalis on sleep disorders, blood pressure, and anthropometric indicators.
Supplementary Information
Acknowledgements
The authors hereby appreciate all the volunteers who participated in this study. The authors would like to gratefully acknowledge the Institute of Medical PlantsJahadDaneshgahi and the nursing staff of the Institute of Endocrinology and Metabolism, Iran University of Medical Sciences, Tehran, Iran, for their assistance in providing the essential facilities for conducting this study.
Abbreviations
- CAM
Complementary and alternative medicine
- DBP
Diastolic blood pressure
- FBS
Fasting blood sugar
- GLUT4
Glucose transporter type 4
- hs-CRP
High-sensitivity C-reactive protein
- IPAQ
International physical activity questionnaire
- PUFA
Polyunsaturated fatty acid
- SBP
Systolic blood pressure
- T2DM
Type 2 diabetes mellitus
- WC
Waist circumference
Authors' contributions
Conceptualization has conducted by Mostafa Safari, Akbar Asadi, NaheedAryaeian/. Methodology has conducted by Mostafa Safari, Akbar Asadi, NaheedAryaeian, Farzadshidfar, ShimaJazayeri, MojtabaMalek, Hasan FallahHuseini, AghaFateme Hosseini. Validation has conducted by NaheedAryaeian, Farzadshidfar, ShimaJazayeri, MojtabaMalek, Hasan FallahHuseini. Formal analysis has conducted by Mostafa Safari, NaheedAryaeian, AghaFateme Hosseini. Investigation has conducted by Mostafa Safari, Akbar Asadi, Zahra hamidi. Resources has conducted by MojtabaMalek, Hasan FallahHuseini. Writing—Original Draft has conducted by Mostafa Safari, NaheedAryaeian. All authors reviewed the manuscript. The author(s) read and approved the final manuscript.
Funding
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
Availability of data and materials
All data generated or analysed during this study are included in this published article [and its supplementary information files].
Declarations
Ethics approval and consent to participate
All protocols in this study were followed conducted in accordance with the Helsinki Declaration (1989 revision)and Ethical approval for this study was obtained from the Iran University of Medical Sciences Ethics committee (IR.IUMS.FMD.REC 1396.9413468004; research.iums.ac.ir). The study was registered at the Iranian Registry of Clinical Trials (IRCT201709239472N16;) Registration date: 09/10/2017. All participants were informed of the purposes of the study, and theysigned a written informed consent.
The Institute of Medicinal Plant Karaj Iran undertook the formal identification of the plant material used in our study. The authors have complied with all relevant institutional and national guidelines and legislation in experimental research and field studies on plants, including the collection of plant materials for this study.
Consent for publication
We declare that this manuscript is original, has not been published before and is not currently being considered for publication elsewhere. The manuscript has been read and approved by all the mentioned authors. All subjects gave informed consent and patient’s anonymity was preserved.
Competing interests
The authors declared no conflict of interest.
Footnotes
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
References
- 1.Alzahrani A, Alghamdi A, Alqarni T, Alshareef R, Alzahrani A. Prevalence and predictors of depression, anxiety, and stress symptoms among patients with type II diabetes attending primary healthcare centers in the western region of Saudi Arabia: a cross-sectional study. Int J Ment Heal Syst. 2019;13(1):48. doi: 10.1186/s13033-019-0307-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Khalighi Z, Badfar G, Mahmoudi L, Soleymani A, Azami M, Shohani M. The prevalence of depression and anxiety in Iranian patients with diabetes mellitus: A systematic review and meta-analysis. Diabetes Metab Syndr. 2019;13:2785. [DOI] [PubMed]
- 3.Gonzalez JS, Peyrot M, McCarl LA, Collins EM, Serpa L, Mimiaga MJ, et al. Depression and diabetes treatment nonadherence: a meta-analysis. Diabetes Care. 2008;31(12):2398–2403. doi: 10.2337/dc08-1341. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Lustman PJ, Anderson RJ, Freedland KE, De Groot M, Carney RM, Clouse RE. Depression and poor glycemic control: a meta-analytic review of the literature. Diabetes Care. 2000;23(7):934–942. doi: 10.2337/diacare.23.7.934. [DOI] [PubMed] [Google Scholar]
- 5.Zhang P, Lou P, Chang G, Chen P, Zhang L, Li T, et al. Combined effects of sleep quality and depression on quality of life in patients with type 2 diabetes. BMC Fam Pract. 2016;17(1):40. doi: 10.1186/s12875-016-0435-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.van Dooren FE, Nefs G, Schram MT, Verhey FR, Denollet J, Pouwer F. Depression and risk of mortality in people with diabetes mellitus: a systematic review and meta-analysis. PloS One. 2013;8(3):e57058. [DOI] [PMC free article] [PubMed]
- 7.Tayefi M, Shafiee M, Kazemi-Bajestani SMR, Esmaeili H, Darroudi S, Khakpouri S, et al. Depression and anxiety both associate with serum level of hs-CRP: a gender-stratified analysis in a population-based study. Psychoneuroendocrinology. 2017;81:63–69. doi: 10.1016/j.psyneuen.2017.02.035. [DOI] [PubMed] [Google Scholar]
- 8.Hayashino Y, Mashitani T, Tsujii S, Ishii H. Elevated levels of hs-CRP are associated with high prevalence of depression in japanese patients with type 2 diabetes: the Diabetes Distress and Care Registry at Tenri (DDCRT 6) Diabetes Care. 2014;37(9):2459–2465. doi: 10.2337/dc13-2312. [DOI] [PubMed] [Google Scholar]
- 9.Gonzalez JS, Fisher L, Polonsky WH. Depression in diabetes: have we been missing something important? Diabetes Care. 2011;34(1):236–239. doi: 10.2337/dc10-1970. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Fava M. Weight gain and antidepressants. J Clin Psychiatry. 2000;61:37–41. [PubMed] [Google Scholar]
- 11.Deuschle M. Effects of antidepressants on glucose metabolism and diabetes mellitus type 2 in adults. Curr Opin Psychiatry. 2013;26(1):60–65. doi: 10.1097/YCO.0b013e32835a4206. [DOI] [PubMed] [Google Scholar]
- 12.Alyasin S, Nabavizadeh SH, Esmaeilzadeh H, Heydari ST, Mosavat SH, Parvizi MM, et al. Efficacy of oral supplementation of whey protein in patients with contact dermatitis: a pilot randomized double-blind placebo-controlled clinical trial. Dermatol Ther. 2020;33(6):e14260. doi: 10.1111/dth.14260. [DOI] [PubMed] [Google Scholar]
- 13.Freeman MP. Complementary and Alternative Medicine (CAM): considerations for the treatment of major depressive disorder. J Clin Psychiatry. 2009;70:4–6. doi: 10.4088/JCP.8157su1c.01. [DOI] [PubMed] [Google Scholar]
- 14.Alemi F, Azimi M, Moeini R, Shirafkan H, Bayani M, Mojahedi M, et al. The effectiveness of leech therapy in the severity of diabetic neuropathy: a randomized controlled trial. Trad Integrat Med. 2022;7(4):375-85.
- 15.Asadi A, Shidfar F, Safari M, Hosseini AF, Fallah Huseini H, Heidari I, et al. Efficacy of Melissa officinalis L.(lemon balm) extract on glycemic control and cardiovascular risk factors in individuals with type 2 diabetes: a randomized, double‐blind, clinical trial. Phytotherapy Res. 2019;33(3):651–9. [DOI] [PubMed]
- 16.Chehroudi S, Fatemi MJ, Isfeedvajani MS, Salehi SH, Akbari H, Samimi R. Effects of Melissa officinalis L. on reducing stress, alleviating anxiety disorders, depression, and insomnia, and increasing total antioxidants in burn patients. Trauma Monthly. 2016;22(4):1-7.
- 17.Haybar H, Javid AZ, Haghighizadeh MH, Valizadeh E, Mohaghegh SM, Mohammadzadeh A. The effects of Melissa officinalis supplementation on depression, anxiety, stress, and sleep disorder in patients with chronic stable angina. Clinical nutrition ESPEN. 2018;26:47–52. doi: 10.1016/j.clnesp.2018.04.015. [DOI] [PubMed] [Google Scholar]
- 18.Alizadeh Behbahani B, Shahidi F. Melissa officinalis essential oil: Chemical compositions, antioxidant potential, total phenolic content and antimicrobial activity. Nutrition and Food Sciences Research. 2019;6(1):17–25. doi: 10.29252/nfsr.6.1.17. [DOI] [Google Scholar]
- 19.Chung MJ, Cho S-Y, Bhuiyan MJH, Kim KH, Lee S-J. Anti-diabetic effects of lemon balm (Melissa officinalis) essential oil on glucose-and lipid-regulating enzymes in type 2 diabetic mice. Br J Nutr. 2010;104(2):180–188. doi: 10.1017/S0007114510001765. [DOI] [PubMed] [Google Scholar]
- 20.Weidner C, Wowro SJ, Freiwald A, Kodelja V, Abdel-Aziz H, Kelber O, et al. Lemon balm extract causes potent antihyperglycemic and antihyperlipidemic effects in insulin-resistant obese mice. Mol Nutr Food Res. 2014;58(4):903–907. doi: 10.1002/mnfr.201300477. [DOI] [PubMed] [Google Scholar]
- 21.Khodsooz S, Moshtaghian J, Eivani M. Antihyperglycemic and antihyperlipidemic effects of hydroalcoholic extract of Melissa officinalis (Lemon Balm) in alloxan-induced diabetic rats. 2016.
- 22.Jandaghi P, Noroozi M, Ardalani H, Alipour M. Lemon balm: A promising herbal therapy for patients with borderline hyperlipidemia—A randomized double-blind placebo-controlled clinical trial. Complement Ther Med. 2016;26:136–140. doi: 10.1016/j.ctim.2016.03.012. [DOI] [PubMed] [Google Scholar]
- 23.Nayebi N, Esteghamati A, Meysamie A, Khalili N, Kamalinejad M, Emtiazy M, et al. The effects of a Melissa officinalis L. based product on metabolic parameters in patients with type 2 diabetes mellitus: A randomized double-blinded controlled clinical trial. J Complement Integr Med. 2019;16(3). [DOI] [PubMed]
- 24.Asadi A, Safari M, Malek M, Hosseini AF, Rezazadeh S, Rajab A, et al. Safety and efficacy of Melissa officinalis (lemon balm) on ApoA-I, Apo B, lipid ratio and ICAM-1 in type 2 diabetes patients: A randomized, double-blinded clinical trial. Complement Ther Med. 2018;40:83–88. doi: 10.1016/j.ctim.2018.07.015. [DOI] [PubMed] [Google Scholar]
- 25.Javid AZ, Haybar H, Dehghan P, Haghighizadeh MH, Mohaghegh SM, Ravanbakhsh M, et al. The effects of Melissa officinalis (lemon balm) in chronic stable angina on serum biomarkers of oxidative stress, inflammation and lipid profile. Asia Pac J Clin Nutr. 2018;27(4):785. doi: 10.6133/apjcn.022018.01. [DOI] [PubMed] [Google Scholar]
- 26.Liu J, Wan Y, Zhao Z, Chen H. Determination of the content of rosmarinic acid by HPLC and analytical comparison of volatile constituents by GC-MS in different parts of Perilla frutescens (L.) Britt. Chem Central J. 2013;7(1):61. [DOI] [PMC free article] [PubMed]
- 27.Beck AT, Steer RA, Brown GK. Beck Depression Inventory Manual. TX: The Psychological Corporation. San Antonio; 1996. p. 1987. [Google Scholar]
- 28.Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry. 1961;4(6):561–571. doi: 10.1001/archpsyc.1961.01710120031004. [DOI] [PubMed] [Google Scholar]
- 29.Beck AT, Epstein N, Brown G, Steer RA. An inventory for measuring clinical anxiety: psychometric properties. J Consult Clin Psychol. 1988;56(6):893. doi: 10.1037/0022-006X.56.6.893. [DOI] [PubMed] [Google Scholar]
- 30.Moghaddam JF, Nakhaee N, Sheibani V, Garrusi B, Amirkafi A. Reliability and validity of the Persian version of the Pittsburgh Sleep Quality Index (PSQI-P) Sleep and Breathing. 2012;16(1):79–82. doi: 10.1007/s11325-010-0478-5. [DOI] [PubMed] [Google Scholar]
- 31.Buysse DJ, Reynolds CF, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry res. 1989;28(2):193–213. doi: 10.1016/0165-1781(89)90047-4. [DOI] [PubMed] [Google Scholar]
- 32.Taiwo AE, Leite FB, Lucena GM, Barros M, Silveira D, Silva MV, et al. Anxiolytic and antidepressant-like effects of Melissa officinalis (lemon balm) extract in rats: Influence of administration and gender. Indian journal of pharmacology. 2012;44(2):189. doi: 10.4103/0253-7613.93846. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Hindmarch I. Expanding the horizons of depression: beyond the monoamine hypothesis. Hum Psychopharmacol Clin Exp. 2001;16(3):203–218. doi: 10.1002/hup.288. [DOI] [PubMed] [Google Scholar]
- 34.Feliú-Hemmelmann K, Monsalve F, Rivera C. Melissa officinalis and Passiflora caerulea infusion as physiological stress decreaser. Int J Clin Exp Med. 2013;6(6):444. [PMC free article] [PubMed] [Google Scholar]
- 35.Alijaniha F, Naseri M, Afsharypuor S, Fallahi F, Noorbala A, Mosaddegh M, et al. Heart palpitation relief with Melissa officinalis leaf extract: double blind, randomized, placebo controlled trial of efficacy and safety. J Ethnopharmacol. 2015;164:378–384. doi: 10.1016/j.jep.2015.02.007. [DOI] [PubMed] [Google Scholar]
- 36.Cases J, Ibarra A, Feuillere N, Roller M, Sukkar SG. Pilot trial of Melissa officinalis L. leaf extract in the treatment of volunteers suffering from mild-to-moderate anxiety disorders and sleep disturbances. Med J Nutrition Metab. 2011;4(3):211–8. [DOI] [PMC free article] [PubMed]
- 37.Tyrer P, Baldwin D. Generalised anxiety disorder. Lancet. 2006;368(9553):2156–2166. doi: 10.1016/S0140-6736(06)69865-6. [DOI] [PubMed] [Google Scholar]
- 38.Awad R, Muhammad A, Durst T, Trudeau VL, Arnason JT. Bioassay‐guided fractionation of lemon balm (Melissa officinalis L.) using an in vitro measure of GABA transaminase activity. Phytotherapy Res. 2009;23(8):1075–81. [DOI] [PubMed]
- 39.Moehler H. GABA A receptors in central nervous system disease: anxiety, epilepsy, and insomnia. J Recept Signal Transduction. 2006;26(5–6):731–740. doi: 10.1080/10799890600920035. [DOI] [PubMed] [Google Scholar]
- 40.Salah SM, Jäger AK. Screening of traditionally used Lebanese herbs for neurological activities. J Ethnopharmacol. 2005;97(1):145–149. doi: 10.1016/j.jep.2004.10.023. [DOI] [PubMed] [Google Scholar]
- 41.Yui S, Fujiwara S, Harada K, Motoike-Hamura M, Sakai M, Matsubara S, et al. Beneficial effects of lemon balm leaf extract on in vitro glycation of proteins, arterial stiffness, and skin elasticity in healthy adults. J Nutr Sci Vitaminol. 2017;63(1):59–68. doi: 10.3177/jnsv.63.59. [DOI] [PubMed] [Google Scholar]
- 42.Hasanein P, Riahi H. Antinociceptive and antihyperglycemic effects of Melissa officinalis essential oil in an experimental model of diabetes. Med Princ Pract. 2015;24(1):47–52. doi: 10.1159/000368755. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43.Maleki G, Hemat-Far A, Heidari N. Short-term effects of Melissa officinalis L. extract supplementation on inflammatory response and the perceived the pain of downhill running in young trained swimmers. Iranian J Med Aromatic Plants. 2016;32(1).
- 44.Tunon M, Garcia-Mediavilla M, Sanchez-Campos S, Gonzalez-Gallego J. Potential of flavonoids as anti-inflammatory agents: modulation of pro-inflammatory gene expression and signal transduction pathways. Curr Drug Metab. 2009;10(3):256–271. doi: 10.2174/138920009787846369. [DOI] [PubMed] [Google Scholar]
- 45.Rocha J, Eduardo-Figueira M, Barateiro A, Fernandes A, Brites D, Bronze R, et al. Anti-inflammatory effect of rosmarinic acid and an extract of Rosmarinus officinalis in rat models of local and systemic inflammation. Basic Clin Pharmacol Toxicol. 2015;116(5):398–413. doi: 10.1111/bcpt.12335. [DOI] [PubMed] [Google Scholar]
- 46.Park BY, Lee H, Woo S, Yoon M, Kim J, Hong Y, et al. Reduction of adipose tissue mass by the angiogenesis inhibitor ALS-L1023 from Melissa officinalis. PLoS One. 2015;10(11):e0141612. [DOI] [PMC free article] [PubMed]
- 47.Moullec G, Plourde A, Lavoie KL, Suarthana E, Bacon SL. Beck Depression Inventory II: determination and comparison of its diagnostic accuracy in cardiac outpatients. Eur J Prev Cardiol. 2015;22(5):665–672. doi: 10.1177/2047487314527851. [DOI] [PubMed] [Google Scholar]
- 48.Smarr KL, Keefer AL. Measures of depression and depressive symptoms: Beck depression Inventory-II (BDI-II), center for epidemiologic studies depression scale (CES-D), geriatric depression scale (GDS), hospital anxiety and depression scale (HADS), and patient health Questionnaire-9 (PHQ-9) Arthritis Care Res. 2011;63(S11):S454–S466. doi: 10.1002/acr.20556. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Data Availability Statement
All data generated or analysed during this study are included in this published article [and its supplementary information files].